First-in-class experimental CAR T-cell therapy shows promise against solid tumors
Researchers with the Charbonneau Cancer Institute at the University of Calgary and McMaster University have identified a unique…
Alzheimer’s plaques decline after CAR-T immune cell treatment in preclinical study
A novel CAR-T cell approach targets amyloid plaques in preclinical Alzheimer models, raising the possibility that engineered immune…
Silica nanomatrix enhances immunotherapy for solid tumors
Cancer has long remained a leading cause of death worldwide and in Hong Kong, accounting for 30% of…
Genetic modification enhances “living drugs” for blood cancers
CAR T cells are patient-derived, genetically engineered immune cells. They are “living drugs” and constitute a milestone in…